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Background
Objectives
Discussion
Study Design
• Retrospective quasi-experimental study, pre-post 
intervention 
• Pre-intervention: April 2017 – September 2019
• Post-intervention: upon IRB approval – May 
2020 
Inclusion Criteria
• ≥ 18 years AND either of the following: 
• History of emergency medical care for 
intoxication or overdose
• Identified risk of opioid overdose
• Pre-intervention: discharged with naloxone 
outpatient prescription 
• Post-intervention: discharged with take home 
naloxone kit or prescription
Exclusion Criteria
• Pregnant women
Development 
• A literature search was performed for evidence-
based evaluation of strengths and limitations of 
similar study design.
• Key stakeholders were identified and engaged to 
determine their interest in the study and to gain 
support. 
• ED physicians to identify at-risk patients and 
prescribe THNK/prescription upon discharge
• ED nurses to provide education to patients, 
family member(s), or friend(s) prior to 
discharge
• Pharmacy informaticists and analysists to 
build THNK order set 
• Pharmacy department to create THNK and 
store in Pyxis 
• Intranasal naloxone was selected as formulation 
of choice based on convenient drug 
administration and ease-of-use for laypeople. 
• Operational and cost consideration were 
reviewed to purchase naloxone 
• Obtained $10,000 grant from a philanthropic 
arm of the hospital to support the initiative 
for uninsured and/or homeless patients
• THNKs to include 2 intranasal naloxone (Narcan), 
a medication guide, and an educational insert.
Challenges
• Prolongation of protocol development due to 
various factors: 
• Determining the inclusion criteria 
• Coordinating with various stakeholders
• Obtaining funds to purchase naloxone 
• Delay in IRB approval due to group of 
patients being identified as “high risk”
• Implementation of protocol postponed given the 
current COVID-19 pandemic 
Future Considerations
• Secure adequate funding for project prior to 
development of a study/protocol 
• Develop a protocol to be reviewed and approved 
by Pharmacy and Therapeutics (P&T) committee 
prior to IRB submission to prevent delays
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• In 2017, more than 70,000 people in the United 
States died from drug overdose; approximately 75% 
of unintentional opioid-overdose deaths occurred 
outside of a medical setting. 
• Naloxone is an opioid antagonist that can rapidly 
reverse an opioid overdose when administered 
properly. 
• Cost, legal concerns, and social stigma are barriers to 
naloxone access.
• Community overdose education and naloxone 
distribution (OEND) programs have demonstrated 
that take-home naloxone kits (THNK) increase 
reversal agent access and are associated with 
reduced opioid-overdose mortality rates. 
• From January 2016 – June 2019, about 4,016 
emergency department (ED) and urgent care visits in 
the Portland tri-county area (Clackamas, Multnomah, 
and Washington) were due to opioid overdose.
• The ED is a critical intervention point for providers 
and pharmacists to engage patients with or at-risk of 
opioid overdose and to provide evidence-based 
therapy such as a take-home naloxone kit.
• To reduce the number of opioid overdose deaths in 
the community 
Methodology
Primary Objective
• To develop and implement a take-home naloxone kit 
protocol in the ED of a large tertiary care hospital 
Secondary Objective(s)
• To increase patient access to opioid reversal agent by 
prescribing and dispensing kits 
• To provide safe medication use and naloxone 
administration technique education to patients, 
family members, and/or friends
Development Process
Health & Services
References
Purpose
Project Timeline 
Next Step 
• Adaptation of parts of the study to take place in 
two large tertiary care hospitals 
Implementation Algorithm
